argenx SE (ARGX) PT Raised to $707 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
Go back to argenx SE (ARGX) PT Raised to $707 at Jefferies
November 21, 2024 5:08 AM EST
Oppenheimer analyst Leland Gershell raised the price target on argenx SE (NASDAQ: ARGX) to $675.00 (from $646.00) while maintaining a Outperform rating.
The analyst comments "Yesterday ARGX announced clinical proof-of-concept in myositis, with subQ efgart yielding statistically-significant improvement across all three myositis subtypes being evaluated in... More
November 21, 2024 1:34 AM EST
Barclays analyst Charles Pitman-King raised the price target on argenx SE (ARGX:BB) (NASDAQ: ARGX) to EUR670.00 (from EUR650.00) while maintaining a Overweight rating.
The analyst comments: "Following the positive GO decision from the P2 analysis of the ongoing P2/3 ALKIVIA trial, noting... More
November 20, 2024 3:57 PM EST
Evercore ISI analyst Gavin Clark-Gartner raised the price target on argenx SE (NASDAQ: ARGX) to $706.00 (from $675.00) while maintaining a Outperform rating.
...
More
November 20, 2024 11:44 AM EST
Raymond James analyst Danielle Brill raised the price target on argenx SE (NASDAQ: ARGX) to $770.00 (from $688.00) while maintaining a Strong Buy rating.
The analyst comments "This morning, ARGX announced their plans to advance development of efgartigimod (SC) into Phase 3 for myositis. The Go decision... More
